Anavex Life Sciences Corp (AVXL)

[sage4]

I am repeating myself. Yes, There're no comparison to A2-73 for all aspects imho.
Dr. Missling said in the last CC:

A dialogue with the agency to share our data with the small molecule,which has the advantage of being easily administrable, does not have any challenging procedures. You don’t need a PET study upfront, you don’t need an MRI study upfront or during the treatment, and you can just go to the physician and be assessed and have Alzheimer disease, and the physician will say, take this capsules or pills and come back in a few weeks or months again. And so this is really a big advantage from our procedure. There’s also no requirement to have a demonstrated level of a better in the brain because in our study it was not required. We measured a better in the brain, but it was not an entry criteria.